Intellectual Property India Publishes Patent Application for 'Fusion Protein Comprising Taci Polypeptide And Use Thereof' Filed by Jiangsu Hengrui Pharmaceuticals Co. Ltd.; and Shanghai Shengdi Pharmaceutical Co. Ltd.

MUMBAI, India, April 4 -- Intellectual Property India has published a patent application (202527017500 A) filed by Jiangsu Hengrui Pharmaceuticals Co. Ltd.; and Shanghai Shengdi Pharmaceutical Co. Ltd., Jiangsu, China, on Feb. 27, for 'fusion protein comprising taci polypeptide and use thereof.'

Inventor(s) include Gao, Han; Wang, Huan; Zhang, Chongqi; Lin, Yuan; Lin, Kan; and Liao, Cheng.

The application for the patent was published on April 4, under issue no. 14/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides a fusion protein comprising a TACI polypeptide and a use thereof, particularly a use for preventing or treating autoimmune diseases."

The patent application was intern...